Thermo Fisher Scientific Inc (NYSE:TMO) had its price target hoisted by Leerink Swann from $190.00 to $207.00 in a research note issued to investors on Monday. Leerink Swann currently has an outperform rating on the medical research company’s stock.
A number of other research firms also recently weighed in on TMO. Zacks Investment Research raised Thermo Fisher Scientific from a hold rating to a buy rating and set a $212.00 price objective on the stock in a report on Thursday, September 21st. Bank of America Corporation reaffirmed a buy rating and set a $210.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. Cowen and Company reaffirmed an outperform rating and set a $220.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a report on Sunday, September 10th. BidaskClub downgraded Thermo Fisher Scientific from a strong-buy rating to a buy rating in a report on Monday, July 31st. Finally, Barclays PLC reissued an overweight rating and issued a $215.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a report on Monday, September 25th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. Thermo Fisher Scientific currently has an average rating of Buy and an average price target of $203.64.
Thermo Fisher Scientific (NYSE TMO) opened at 193.39 on Monday. The firm’s 50-day moving average price is $188.78 and its 200-day moving average price is $174.98. Thermo Fisher Scientific has a 12-month low of $139.07 and a 12-month high of $194.30. The company has a market cap of $75.45 billion, a P/E ratio of 33.69 and a beta of 1.05.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating analysts’ consensus estimates of $2.27 by $0.03. The company had revenue of $5 billion for the quarter, compared to the consensus estimate of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.03 earnings per share. Analysts expect that Thermo Fisher Scientific will post $9.35 EPS for the current year.
In related news, VP Seth H. Hoogasian sold 4,140 shares of the business’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $177.80, for a total value of $736,092.00. Following the completion of the transaction, the vice president now owns 25,518 shares in the company, valued at approximately $4,537,100.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jim P. Manzi sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $175.20, for a total transaction of $175,200.00. Following the completion of the transaction, the director now owns 38,757 shares of the company’s stock, valued at approximately $6,790,226.40. The disclosure for this sale can be found here. Insiders sold a total of 52,738 shares of company stock valued at $9,302,112 in the last 90 days. 0.49% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of TMO. Proficio Capital Partners LLC raised its position in Thermo Fisher Scientific by 71.5% in the 1st quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock worth $105,000 after purchasing an additional 253 shares during the last quarter. Chicago Partners Investment Group LLC bought a new position in Thermo Fisher Scientific in the 2nd quarter worth approximately $108,000. Cribstone Capital Management LLC raised its position in Thermo Fisher Scientific by 8.7% in the 2nd quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock worth $109,000 after purchasing an additional 50 shares during the last quarter. Sharkey Howes & Javer raised its position in Thermo Fisher Scientific by 1.0% in the 1st quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after purchasing an additional 7 shares during the last quarter. Finally, Shine Investment Advisory Services Inc. bought a new position in Thermo Fisher Scientific in the 2nd quarter worth approximately $113,000. Hedge funds and other institutional investors own 83.36% of the company’s stock.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.